Sancilio Pharmaceuticals Company, Inc., along with two subsidiaries and affiliates, has filed a petition for relief under Chapter 11 in the Bankruptcy Court for the District of Delaware (Lead Case No. 18-11333). Sancilio, based in Riviera Beach, Florida, develops and markets a variety of pharmaceutical products, including products based on Sancilio’s proprietary Advanced Lipid Technologies platform, a group of drug delivery systems designed to improve the body’s ability to break down and use lipophilic compounds (which include many active pharmaceutical ingredients). Sancilio recently presented the results of a Phase 2 Study for Altemia, a product being developed for the treatment of Sickle Cell Disease. Sancilio’s petition estimates both its assets and liabilities to be between $10 – $50 million. The First Day Declaration has not yet been filed. Sancilio has not yet proposed a claims and noticing agent. Assignment of the cases is pending.